JP2017503030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503030A5 JP2017503030A5 JP2016565135A JP2016565135A JP2017503030A5 JP 2017503030 A5 JP2017503030 A5 JP 2017503030A5 JP 2016565135 A JP2016565135 A JP 2016565135A JP 2016565135 A JP2016565135 A JP 2016565135A JP 2017503030 A5 JP2017503030 A5 JP 2017503030A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- receptor antagonist
- crf1 receptor
- nbi
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002464 receptor antagonist Substances 0.000 claims description 36
- 229940044551 receptor antagonist Drugs 0.000 claims description 36
- 108091005471 CRHR1 Proteins 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 12
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 12
- 229960000258 corticotropin Drugs 0.000 claims description 12
- 230000027288 circadian rhythm Effects 0.000 claims description 10
- 238000010494 dissociation reaction Methods 0.000 claims description 9
- 230000005593 dissociations Effects 0.000 claims description 9
- VKHVAUKFLBBZFJ-SFHVURJKSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-[(1s)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N([C@@H](CC)C=1ON=C(C)N=1)C(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1C VKHVAUKFLBBZFJ-SFHVURJKSA-N 0.000 claims description 8
- -1 3-methyl-1 , 2,4-oxadiazol-5-yl Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- AKLMUGFDGONMAA-UHFFFAOYSA-N 268545-87-5 Chemical compound C=12C3=NC(C)=CC=1N(C(CCC)CCC)CCN2N=C3C1=CC=C(Cl)C=C1Cl AKLMUGFDGONMAA-UHFFFAOYSA-N 0.000 claims description 5
- QBBJSFUFEUXTNU-UHFFFAOYSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(NC(CC)CC)=CC(C)=NC2=C1C1=CC=C(OC)C=C1C QBBJSFUFEUXTNU-UHFFFAOYSA-N 0.000 claims description 5
- ANNRUWYFVIGKHA-UHFFFAOYSA-N 3-[6-(dimethylamino)-4-methylpyridin-3-yl]-2,5-dimethyl-n,n-dipropylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(N(CCC)CCC)=CC(C)=NC2=C1C1=CN=C(N(C)C)C=C1C ANNRUWYFVIGKHA-UHFFFAOYSA-N 0.000 claims description 5
- IEAKXXNRGSLYTQ-DEOSSOPVSA-N SSR 125543 Chemical compound C1=C(C)C(OC)=CC(Cl)=C1C1=C(C)SC(N(CC#C)[C@@H](CC2CC2)C=2C=C(F)C(C)=CC=2)=N1 IEAKXXNRGSLYTQ-DEOSSOPVSA-N 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 230000001780 adrenocortical effect Effects 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- JAVQQLIFVFPAQG-UHFFFAOYSA-N 2-phenyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=2NC=CC=2C(N)=NC=1C1=CC=CC=C1 JAVQQLIFVFPAQG-UHFFFAOYSA-N 0.000 claims description 3
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- WPFZGADUIUVTCF-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound NC1=CC=NC2=CC=NN12 WPFZGADUIUVTCF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019043466A JP6936825B2 (ja) | 2014-01-21 | 2019-03-11 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929941P | 2014-01-21 | 2014-01-21 | |
| US61/929,941 | 2014-01-21 | ||
| US201461981033P | 2014-04-17 | 2014-04-17 | |
| US61/981,033 | 2014-04-17 | ||
| US201462069155P | 2014-10-27 | 2014-10-27 | |
| US62/069,155 | 2014-10-27 | ||
| PCT/US2015/012315 WO2015112642A1 (en) | 2014-01-21 | 2015-01-21 | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019043466A Division JP6936825B2 (ja) | 2014-01-21 | 2019-03-11 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503030A JP2017503030A (ja) | 2017-01-26 |
| JP2017503030A5 true JP2017503030A5 (cg-RX-API-DMAC7.html) | 2018-03-01 |
| JP6585625B2 JP6585625B2 (ja) | 2019-10-02 |
Family
ID=52450623
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565135A Active JP6585625B2 (ja) | 2014-01-21 | 2015-01-21 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2019043466A Active JP6936825B2 (ja) | 2014-01-21 | 2019-03-11 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2020099865A Active JP7104743B2 (ja) | 2014-01-21 | 2020-06-09 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2021184620A Withdrawn JP2022010260A (ja) | 2014-01-21 | 2021-11-12 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2024079330A Pending JP2024098001A (ja) | 2014-01-21 | 2024-05-15 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019043466A Active JP6936825B2 (ja) | 2014-01-21 | 2019-03-11 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2020099865A Active JP7104743B2 (ja) | 2014-01-21 | 2020-06-09 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2021184620A Withdrawn JP2022010260A (ja) | 2014-01-21 | 2021-11-12 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| JP2024079330A Pending JP2024098001A (ja) | 2014-01-21 | 2024-05-15 | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
Country Status (24)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068315T2 (hu) * | 2014-01-21 | 2024-12-28 | Neurocrine Biosciences Inc | CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére |
| CA2940242A1 (en) | 2014-02-20 | 2015-08-27 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
| AU2017324942B2 (en) | 2016-09-07 | 2022-01-27 | The Regents Of The University Of California | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-Tau and improve cognition |
| BR112020002967A2 (pt) * | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| EP4438124A3 (en) * | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| JP7532328B2 (ja) * | 2018-12-07 | 2024-08-13 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態 |
| TW202446384A (zh) * | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| JP2022541550A (ja) * | 2019-07-19 | 2022-09-26 | スプルース バイオサイエンシーズ，インク． | 先天性副腎過形成を処置する方法 |
| CA3152590A1 (en) * | 2019-09-27 | 2021-04-01 | Evan Smith | Crf receptor antagonists and methods of use |
| IL298901A (en) * | 2020-06-10 | 2023-02-01 | Neurocrine Biosciences Inc | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia |
| EP4175572A4 (en) | 2020-08-12 | 2024-03-27 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4949582B1 (cg-RX-API-DMAC7.html) | 1969-01-20 | 1974-12-27 | ||
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| US6664261B2 (en) | 1996-02-07 | 2003-12-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as CRF receptor antagonists |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| CA2265672C (en) | 1996-09-16 | 2008-12-02 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| JP2002501492A (ja) | 1997-04-22 | 2002-01-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｒｆアンタゴニストのキノ−及びキナゾリン類 |
| WO1999010350A1 (en) | 1997-08-22 | 1999-03-04 | Du Pont Pharmaceuticals Company | NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS |
| US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| EP1165517A1 (en) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators |
| FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
| FR2802530B1 (fr) | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| US7276526B2 (en) | 2001-07-13 | 2007-10-02 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
| CN1917882A (zh) | 2004-02-13 | 2007-02-21 | 辉瑞产品公司 | 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合 |
| EP1781257B1 (en) | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| ES2326827T3 (es) | 2004-10-19 | 2009-10-20 | Smithkline Beecham (Cork) Limited | Anatagonistas del receptor de crf y metodos relacionados. |
| EP1869049B1 (en) | 2005-03-21 | 2009-03-04 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2006107784A1 (en) | 2005-04-05 | 2006-10-12 | Eli Lilly And Company | Imidazopyridazine compounds |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| US20090234117A1 (en) | 2005-05-27 | 2009-09-17 | Toshihiko Kashiwagi | Pyrazolopyrimidine Derivative |
| EP1957056A2 (en) | 2005-11-10 | 2008-08-20 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| EP1961745A1 (en) | 2005-12-12 | 2008-08-27 | Ono Pharmaceutical Co., Ltd. | Bicyclic heterocyclic compound |
| EP1961754A4 (en) | 2005-12-15 | 2009-11-11 | Ono Pharmaceutical Co | BICYCLIC HETEROCYCLIC COMPOUND |
| US8153127B2 (en) | 2006-02-07 | 2012-04-10 | Phenoquest Ag | Method of treating depression |
| EP1834641A1 (en) | 2006-03-16 | 2007-09-19 | Sanofi-Aventis | Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia |
| MX2008014843A (es) | 2006-05-22 | 2008-12-05 | Vanda Pharmaceuticals Inc | Tratamiento de trastornos depresivos. |
| AU2007297421B2 (en) | 2006-09-20 | 2012-03-08 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as CRF1 receptor antagonists |
| MX2009003098A (es) | 2006-09-20 | 2009-04-01 | Lilly Co Eli | Compuestos de tiofen pirazolopirimidina. |
| EP2088861A4 (en) | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | Benzimidazole compounds |
| WO2008083070A1 (en) | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
| US8039500B2 (en) | 2006-12-29 | 2011-10-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
| WO2009008552A1 (en) | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
| WO2009144632A1 (en) | 2008-05-30 | 2009-12-03 | Pfizer Limited | Novel compounds |
| US7932256B2 (en) | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
| JP2011529899A (ja) | 2008-07-31 | 2011-12-15 | ブリストル−マイヤーズ スクイブ カンパニー | 副腎皮質刺激ホルモン放出因子受容体活性のモジュレーターとしての置換カルバメート誘導体 |
| US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| JP5800428B2 (ja) | 2008-11-03 | 2015-10-28 | ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 調整式ロッド組立体 |
| WO2010096426A2 (en) | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
| HUP0900267A2 (en) | 2009-04-30 | 2011-03-28 | Sanofi Aventis | Process for preparing of thiazole amines and intermediates thereof |
| AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| JPWO2011043387A1 (ja) | 2009-10-08 | 2013-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロオキサゾール化合物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| US10301290B2 (en) | 2012-04-13 | 2019-05-28 | Epizyme, Inc. | Combination therapy for treating cancer |
| US20150094310A1 (en) | 2012-04-23 | 2015-04-02 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| US20150278438A1 (en) * | 2012-04-23 | 2015-10-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Genetic predictors of response to treatment with crhr1 antagonists |
| HUE068315T2 (hu) | 2014-01-21 | 2024-12-28 | Neurocrine Biosciences Inc | CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére |
| WO2016065177A1 (en) | 2014-10-22 | 2016-04-28 | The Trustees Of The University Of Pennsylvania | Method of treating depression and other stress related disorders |
| RU2736509C2 (ru) | 2015-02-06 | 2020-11-17 | Ньюрокрайн Байосайенсиз, Инк. | [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы |
| EP3277836B1 (en) | 2015-04-02 | 2019-02-27 | HMNC Value GmbH | Method of treatment using genetic predictors of a response to treatment with ssr-125543 |
| KR102372032B1 (ko) * | 2016-07-14 | 2022-03-08 | 가부시키가이샤 코나미 데지타루 엔타테인멘토 | 게임 시스템, 단말 장치 및 프로그램 |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| WO2018219804A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
| WO2019036472A1 (en) | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| EP4438124A3 (en) * | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| JP2022541550A (ja) | 2019-07-19 | 2022-09-26 | スプルース バイオサイエンシーズ，インク． | 先天性副腎過形成を処置する方法 |
| CA3152590A1 (en) | 2019-09-27 | 2021-04-01 | Evan Smith | Crf receptor antagonists and methods of use |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| IL298901A (en) | 2020-06-10 | 2023-02-01 | Neurocrine Biosciences Inc | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia |
| US20240024330A1 (en) | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
-
2015
- 2015-01-21 HU HUE15702917A patent/HUE068315T2/hu unknown
- 2015-01-21 NZ NZ722122A patent/NZ722122A/en unknown
- 2015-01-21 CN CN202010134003.XA patent/CN111228274A/zh active Pending
- 2015-01-21 CN CN201580005270.4A patent/CN106102740A/zh active Pending
- 2015-01-21 US US15/113,362 patent/US20170020877A1/en not_active Abandoned
- 2015-01-21 LT LTEPPCT/US2015/012315T patent/LT3096756T/lt unknown
- 2015-01-21 IL IL317035A patent/IL317035A/en unknown
- 2015-01-21 EP EP15702917.4A patent/EP3096756B1/en active Active
- 2015-01-21 PT PT157029174T patent/PT3096756T/pt unknown
- 2015-01-21 IL IL304134A patent/IL304134B2/en unknown
- 2015-01-21 RS RS20240910A patent/RS65839B1/sr unknown
- 2015-01-21 ES ES15702917T patent/ES2984706T3/es active Active
- 2015-01-21 HR HRP20241046TT patent/HRP20241046T1/hr unknown
- 2015-01-21 BR BR112016016975-1A patent/BR112016016975B1/pt active IP Right Grant
- 2015-01-21 AU AU2015209452A patent/AU2015209452C1/en active Active
- 2015-01-21 PL PL15702917.4T patent/PL3096756T3/pl unknown
- 2015-01-21 WO PCT/US2015/012315 patent/WO2015112642A1/en not_active Ceased
- 2015-01-21 SM SM20240361T patent/SMT202400361T1/it unknown
- 2015-01-21 MX MX2016009499A patent/MX389004B/es unknown
- 2015-01-21 RU RU2016133972A patent/RU2718918C2/ru active
- 2015-01-21 CA CA3155599A patent/CA3155599A1/en active Pending
- 2015-01-21 DK DK15702917.4T patent/DK3096756T3/da active
- 2015-01-21 KR KR1020167022375A patent/KR102258522B1/ko active Active
- 2015-01-21 JP JP2016565135A patent/JP6585625B2/ja active Active
- 2015-01-21 EP EP24174933.2A patent/EP4450070A1/en active Pending
- 2015-01-21 CA CA2936974A patent/CA2936974A1/en active Pending
- 2015-01-21 SI SI201532025T patent/SI3096756T1/sl unknown
- 2015-01-21 FI FIEP15702917.4T patent/FI3096756T3/fi active
- 2015-01-21 KR KR1020217015795A patent/KR20210064407A/ko not_active Ceased
- 2015-01-21 IL IL296683A patent/IL296683B2/en unknown
-
2016
- 2016-07-14 IL IL246783A patent/IL246783B/en unknown
- 2016-07-21 MX MX2022000080A patent/MX2022000080A/es unknown
- 2016-07-21 MX MX2021012539A patent/MX2021012539A/es unknown
-
2018
- 2018-12-20 US US16/227,127 patent/US10905690B2/en active Active
-
2019
- 2019-03-11 JP JP2019043466A patent/JP6936825B2/ja active Active
-
2020
- 2020-06-09 JP JP2020099865A patent/JP7104743B2/ja active Active
- 2020-07-20 AU AU2020207774A patent/AU2020207774B2/en active Active
- 2020-10-20 US US17/074,845 patent/US11730739B2/en active Active
-
2021
- 2021-08-04 US US17/393,553 patent/US11311544B2/en active Active
- 2021-09-29 IL IL286782A patent/IL286782A/en unknown
- 2021-11-12 JP JP2021184620A patent/JP2022010260A/ja not_active Withdrawn
-
2022
- 2022-10-31 AU AU2022263460A patent/AU2022263460B2/en active Active
-
2023
- 2023-07-14 US US18/222,011 patent/US20240058342A1/en active Pending
-
2024
- 2024-05-15 JP JP2024079330A patent/JP2024098001A/ja active Pending
- 2024-09-17 AU AU2024219813A patent/AU2024219813A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503030A5 (cg-RX-API-DMAC7.html) | ||
| RU2016133972A (ru) | Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| EA201991786A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
| RU2016141569A (ru) | Комбинации | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| NZ723859A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
| MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| JP2015532292A5 (cg-RX-API-DMAC7.html) | ||
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| JP2015516392A5 (cg-RX-API-DMAC7.html) | ||
| JP2013512923A5 (cg-RX-API-DMAC7.html) | ||
| NZ718430A (en) | Heterocyclic compounds and uses thereof | |
| AR073079A1 (es) | Compuestos triazolopiridina como inhibidores de pim cinasa | |
| NZ723860A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
| MX2013005445A (es) | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). | |
| MX379425B (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia. | |
| JP2017503014A5 (cg-RX-API-DMAC7.html) | ||
| DE602008003322D1 (de) | Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose | |
| JP2017513809A5 (cg-RX-API-DMAC7.html) | ||
| JP2015526391A5 (cg-RX-API-DMAC7.html) | ||
| JP2016539156A5 (cg-RX-API-DMAC7.html) | ||
| JP2015525798A5 (cg-RX-API-DMAC7.html) | ||
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators |